¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"factor VIII antibody"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
  • psychological factor
    ½É¸®¿äÀÎ
  • psychosocial factor
    ½É¸®»çȸ¿äÀÎ
  • phantom scatter factor
    ÆÒÅÒ»ê¶õ°è¼ö
  • quality factor
    1. Áú¿ä¼Ò 2. Á¤¼ºÀÎÀÚ
  • racial factor
    ÀÎÁ¾¿äÀÎ
  • realization factor
    ½ÇÇöÀÎÀÚ
  • recruitment factor
    µ¿¿øÀÎÀÚ
  • reducing factor
    ȯ¿øÀÎÀÚ
  • reinforcing factor
    °­È­¿äÀÎ
  • relaxing factor
    ÀÌ¿ÏÀÎÀÚ
  • radiation weighting factor
    ¹æ»ç¼±°¡Áß°è¼ö
  • resistance factor
    ³»¼ºÀÎÀÚ, ÀúÇ×ÀÎÀÚ
  • resistance transfer factor
    ³»¼ºÀü´ÞÀÎÀÚ
  • reticuloendothelial depressant factor
    ±×¹°³»Çǰè¾ïÁ¦ÀÎÀÚ, ¸Á»ó³»Çǰè¾ïÁ¦ÀÎÀÚ
  • rheumatoid factor
    ·ù¸¶Æ¼½ºÀÎÀÚ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
  • skin vascular permeability factor
    ÇǺÎÇ÷°üÅõ°úÀÎÀÚ
  • somatotropin release inhibiting factor
    ¼ºÀåÈ£¸£¸óÀ¯¸®¾ïÁ¦ÀÎÀÚ
  • spreading factor
    È®»êÀÎÀÚ
  • stable factor
    ¾ÈÁ¤ÀÎÀÚ
  • stroma factor
    ¹öÆÀÁúÀÎÀÚ
  • sunprotective factor
    Àϱ¤º¸È£Áö¼ö
  • testis-determining factor
    °íȯ°áÁ¤ÀÎÀÚ
  • therapeutic gain factor
    Ä¡·áÀ̵æ°è¼ö
  • thyrotrophin releasing factor
    ¹æÆÐ»ùÀÚ±ØÈ£¸£¸óÀ¯¸®ÀÎÀÚ, °©»ó»ùÀÚ±ØÈ£¸£¸óÀ¯¸®ÀÎÀÚ
  • time-dose factor
    ½Ã°£¼±·®ÀÎÀÚ
  • tissue factor
    Á¶Á÷ÀÎÀÚ
  • transfer factor
    Àü´ÞÀÎÀÚ
  • transforming growth factor
    Àüȯ¼ºÀåÀÎÀÚ
  • transmission factor
    Åõ°ú°è¼ö
  • tumor angiogenesis factor
    Á¾¾çÇ÷°üÇü¼ºÀÎÀÚ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
  • antibody, complement binding
    º¸Ã¼°áÇÕÇ×ü
  • antibody, complement fixing
    º¸Ã¼°áÇÕÇ×ü
  • antibody, cross-reacting
    ±³Â÷¹ÝÀÀÇ×ü
  • antibody, cytolytic
    ¼¼Æ÷¿ëÇØÇ×ü
  • antibody, cytophilic
    ¼¼Æ÷ģȭ¼ºÇ×ü
  • antibody, cytotoxic
    ¼¼Æ÷µ¶¼ºÇ×ü
  • antibody, cytotropic
    ¼¼Æ÷ģȭ¼ºÇ×ü
  • antibody, enzyme-labelled
    È¿¼ÒÇ¥ÁöÇ×ü
  • antibody, ferritin-labelled
    Æä¸®Æ¾Ç¥ÁöÇ×ü
  • antibody, fluorescein-labelled
    Çü±¤Ç¥ÁöÇ×ü
  • antibody, hemolytic
    ¿ëÇ÷¼ºÇ×ü
  • antibody, heterocytotropic
    ÀÌÁ¾¼¼Æ÷ ģȭ¼ºÇ×ü
  • antibody, heterophile
    ÀÌÁ¾Ç׿ø ģȭ¼ºÇ×ü
  • antibody, homocytotropic
    µ¿Á¾¼¼Æ÷ģȭ¼ºÇ×ü
  • antibody, hybrid
    ÇÏÀ̺긮µåÇ×ü
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
  • immobilizing antibody
    ¿îµ¿¾ïÁ¦Ç×ü.
  • incomplete antibody
    ºÒ¿ÏÀüÇ×ü
  • incomplete antibody
    ºÒ¿ÏÀüÇ×ü.
  • indirect fluorescent antibody technique
    °£Á¢Çü±¤Ç×ü¹ý
  • indirect immunofluorescence antibody
    °£Á¢¸é¿ªÇü±¤Ç×ü
  • inhibiting antibody
    ¾ïÁ¦Ç×ü.
  • instructive theory of antibody production
    Áö·É¼³ (Ç×ü»ý»ê)
  • isogenic antibody
    µ¿Á¾Ç×ü(ÔÒðúù÷ô÷).
  • jo-1 antibody
    Jo-1 Ç×ü(ù÷ô÷)
  • label(l)ed antibody
    Ç¥ÁöÇ×ü(¡­ù÷ô÷).
  • labeled antibody
    Ç¥ÁöÇ×ü(¡­ù÷ô÷).
  • macrophage cytophilic antibody
    ´ë½Ä¼¼Æ÷ģȭÇ×ü(ÓÞãÝá¬øàöÑûúù÷ô÷).
  • measles virus antibody
    È«¿ª¹ÙÀÌ·¯½ºÇ×ü
  • mitochondrial antibody
    »ç¸³Ã¼Ç×ü
  • monoclonal antibody
    ´ÜÀÏŬ·Ð¼º Ç×ü(Ó¤ìé¡­àõ ù÷ô÷)
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
  • separation factor
    ºÐ¸®ÀÎÀÚ(ÝÂ×îì×í­)
  • serum prothrombin converting factor
    Ç÷û(úìôè) ÇÁ·ÎÆ®·Òºó ÀüȯÀÎÀÚ(ï®üµì×í­)
  • serum sulfation factor
    Ç÷û À¯È²È­ÀÎÀÚ(úìôè×¼üÜûùì×í­)
  • serum thymic factor
    Ç÷û °©»ó¼±ÀÎÀÚ(úìôèË£ßÒàÍì×í­)
  • sex factor
    ¼ºÀÎÀÚ(àõì×í­)
  • shape factor
    ¸ð¾çÀÎÀÚ(Ù¼åÆì×í­)
  • sigma factor
    ½Ã±×¸¶ÀÎÀÚ(ì×í­)
  • SLR factor
    SLRÀÎÀÚ(ì×í­)
  • somatotropin factor
    ¼Ò¸¶Å䯮·ÎÇÉ ÀÎÀÚ(ì×í­)
  • specificity factor
    ƯÀ̼º ÀÎÀÚ(÷åì¶àõì×í­)
  • spreading factor
    ÆÛÁü ÀÎÀÚ(ì×í­)
  • stable factor
    ¾ÈÁ¤ÀÎÀÚ(äÌïÒì×í­)
  • steric factor
    ÀÔü ÀÎÀÚ(Ø¡ô÷ì×í­)
  • stringent factor
    ¾ö°Ý ÀÎÀÚ (åñÌ«ì×í­)
  • Stuart factor
    ½ºÆ©¾Æ¸£Æ® ÀÎÀÚ(ì×í­)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 15
FF degree of fineness of abrasive particles; fat-free; father factor; fecal frequency; fertility factor...
GF gastric fistula; gastric fluid; germ-free; glass factor; glomerular filtration; gluten-free; grandfa...
GIF gastric intrinsic factor; growth hormone-inhibiting factor
HGF hepatocyte growth factor; hyperglycemic-glucogenolytic factor
HLF heat-labile factor; hepatic leukemia factor
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 15
HBc AB Hepatitis B core antibody
HBsAb Hepatitis B surface antibody
HAMA Human anti-mouse antibody
HAMA Human anti-murine antibody
HuMAb Human monoclonal antibody
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 15
Christmas factor <chemical> Storage-stable blood coagulation factor acting in the intrinsic pathway. Its activated form, ixa, forms a complex with factor viii and calcium on platelet factor 3 to activate factor x to xa. Deficiency of factor ix results in christmas disease (haemophilia b).
Chemical name: Blood-coagulation factor IX
(12 Dec 1998)
christmas factor assay A test used to measure the activity of a blood clotting factor IX (Christmas factor). This test may be used to evaluate excessive bleeding. Abnormally low factor IX assays may be seen in the following conditions: congenital deficiency of factor IX, fat malabsorption, heparin administration, cirrhosis, vitamin K deficiency and warfarin administration.
(27 Sep 1997)
ciliary neurotrophic factor <growth factor> Neurotrophic factor originally characterised as a survival factor for chick ciliary neurons in vitro.
Subsequently shown to promote the survival of a variety of other neuronal cell types and to promote the differentiation of bipotential O2A progenitor cells to type 2 astrocytes in vitro.
Molecular cloning and expression studies indicate that CNTF is a cytosolic protein. Developmental expression and regional distribution studies show that, unlike NGF, CNTF is not a target derived neurotrophic factor.
(18 Nov 1997)
migration-inhibitory factor <growth factor> A soluble, nondialysable factor that is produced by sensitised lymphocytes following exposure to a specific antigen. It inhibits macrophage migration and causes adherence.
It was originally defined on the basis of inhibition of emigration of mononuclear cells from capillary (haematocrit) tubes, more recently a 13 kD protein with migration inhibitory activity has been isolated.
Acronym: MIF
Synonym: inhibition factor.
(22 Sep 2002)
migration-inhibitory factor test A test which measures the presence of migration-inhibitory factor. Usually peritoneal macrophages are placed in a capillary tube in the presence or absence of supernatants from activated T-cells. If MIF is present, the migration of monocyte/macrophages is reduced.
Synonym: macrophage migration inhibition test, migration inhibition test.
(05 Mar 2000)
citrovorum factor N5Formyl-5,6,7,8-tetrahydrofolic acid;the active form of folic acid which acts as a formyl group carrier in transformylation reactions; the calcium salt, leucovorin calcium, has therapeutic use.
Synonym: citrovorum factor, leucovorin.
(05 Mar 2000)
milk factor Member of the retrovirus subfamily Oncornavirinae, antigenically distinct from the murine leukaemia-sarcoma complex, that is associated with adenocarcinomatous tumours of the mammary gland, commonly latent in wild and laboratory mice and causing cancer only in genetically susceptible strains under certain hormonal influences.
Synonym: Bittner agent, Bittner virus, Bittner's milk factor, mammary cancer virus of mice, milk factor, mouse mammary tumour virus.
(05 Mar 2000)
clotting factor <haematology> A group of chemical constituents of the blood (factors I to XIII) which interact to make the blood clot.
(13 Nov 1997)
coagulation factor <haematology> Group of plasma protein substances (Factor I-XIII) contained in the plasma, which act in concert to bring about blood coagulation. Many of the factors contain EGF like domains.
(29 Sep 1997)
coagulation factor XI <haematology> A plasma serine protease with an apple domain.
(18 Nov 1997)
cobra venom factor A component of cobra venom that renders C3 proactivator (properdin factor B) susceptible to factor D of the properdin system, leading to activation of C3 and other components of complement and lysis of unsensitised erythrocytes.
(05 Mar 2000)
coenzyme factor <enzyme> An enzyme oxidizing dihydrolipoamide at the expense of NAD+; completes the oxidative decarboxylation of pyruvate; a part of several enzyme complexes (e.g., alpha-ketoglutarate dehydrogenase complex). Decreased activity leads to neuronal loss in brain resulting in psychomotor retardation.
Synonym: coenzyme factor, lipoamide dehydrogenase, lipoamide reductase (NADH), lipoyl dehydrogenase.
(05 Mar 2000)
monocyte chemotactic and activating factor Cytokine of the C C subfamily, co induced with IL-8 on stimulation of endothelial cells, fibroblasts or monocytes that activates and is chemotactic for, monocytes. A chemokine.
(18 Nov 1997)
monocyte derived neutrophil chemotactic factor <cytokine> A cytokine that activates neutrophils and attracts neutrophils and T-lymphocytes.
It is released by several cell types including monocytes, macrophages, T-lymphocytes, fibroblasts, endothelial cells, and keratinocytes by an inflammatory stimulus. Il-8 is a member of the beta-thromboglobulin superfamily and structurally related to platelet factor 4.
Acronym: IL-8
(12 Dec 1998)
colony-stimulating factor <cell biology> A glycoprotein growth factor that regulates the differentiation of particular cells.
These substances act in either paracrine or autocrine fashion on marrow cells, appear to act synergistically and can exert actions on several lines of progenitor cells, and influence end cell function. These lymphokines induce the maturation and proliferation of white blood cells from the primitive cell types present in bone marrow such as the leucocyte, macrophage and monocyte lines.
These substances can also be made by recombinant DNA technology for use clinically to speed bone marrow recovery typically following chemotherapy.
Acronym: CSF
(18 Jul 2002)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 15
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 15
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 15
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 15
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 15
ÅëÇÕ°Ë»ö ¿Ï·á